ClinicalTrials.gg
CompletedNCT04187560Updated Dec 10, 2020

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

A Phase 1 interventional study of LB-102 in Schizophrenia, sponsored by LB Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-10.

Sponsored by LB Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
670th of 1,319
64 · median 66
Started
2020
with 43 others
Phase 1
196 of 1,465
10 open now
Registered
1,156th of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 670th largest by enrollment of the 1,319 interventional ones that give a count, is one of 44 that started in 2020, is one of 196 in phase 1, and was the 1,156th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study of LB-102 N-Methyl amisulpride) in healthy volunteers. The primary objective is to evaluate the safety and the tolerability of a single oral dose (SAD) and multiple oral doses (MAD) of LB-102 as compared to placebo. The secondary objectives are to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of LB-102.

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of LB-102 in healthy subjects. The study will consist of two parts: Part A - Single Ascending Dose and Part B - Multiple Ascending Doses. There will be 5 cohorts in Part A and 3 Cohorts in Part B of this study. Each cohort consists of 8 subjects, with 6 subjects assigned to LB-102 and 2 subjects assigned to placebo.

In Parts A and B, eligible subjects will be randomized on Day 1 (pre-dose) to placebo (n=2) or LB-102 (n=6). Eligible subjects will receive 1 dose on Day 1 (Part A) or 13 doses on Days 1-7 (Part B) of placebo or LB-102.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects may be included in the study only if they meet all of the following criteria:

  1. Competent to provide .
  2. Voluntarily provide informed consent.
  3. Healthy adult male and female subjects between 18 to 55 years of age inclusive at the screening visit.
  4. (BMI) ≥ 18 and ≤ 30 kg/m2 at screening visit.
  5. Subjects must be in good general health as determined by medical history and physical examination with no medical findings and no history of significant medical disease (e.g. cardiovascular, pulmonary, renal, etc.) or acute condition with the past 30 days.
  6. Have normal clinical laboratory test results and , which are not considered to be clinically significant by the investigator.
  7. Female subjects of must agree to use two methods of an acceptable method of (e.g., condom and spermicide, intrauterine device (IUD), oral contraception which has been stable for 30 days) and at least 90 days after stopping the product. Female subjects using oral contraception whose partner consistently uses condoms or who is vasectomized is also acceptable.
  8. Male subjects must be surgically sterile or practicing at least one method of contraception, from initial study drug administration through 90 days after administration of the last dose of study drug:
  9. Male subjects must agree to abstain from sperm donation through 90 days after administration of the last dose of investigational drug.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study for any of the following reasons:

  1. Are pregnant or lactating.
  2. Have a history or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders which, in the opinion of the investigator, increases the risk of the study drug or may confound the interpretation of study measures.
  3. abnormal findings on physical examination, vital signs, or .
  4. History or presence of psychiatric or neurological disease or condition.
  5. History of seizures.
  6. Subject with any history or current evidence of suicidal behavior.
  7. Unwilling to complete any planned study assessments, including the Columbia-Suicide Severity Rating Scale (CSSRS).
  8. Recent history of alcohol or drug abuse (within the last two years).
  9. Any use of tobacco or tobacco-containing products (cigarettes, pipes, etc.) within one month prior to screening.
  10. Have a history of blood donation in excess of 500 mL of blood within 30 days prior to Screening.
  11. Have received treatment with an drug or device within 30 days prior to Screening.
  12. Use of any prescription or over the counter medication, herbal medications, vitamins, or supplements within 14 days prior to study drug administration.
  13. Have a positive test for (HIV) antibodies 1 and 2, surface antigen or antibody.
  14. Any subject who is known to be allergic to the study drug or any components of the study drug.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Double (Participant, Care provider)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Part A Cohort 1

    LB-102 50 mg (n=6) or Matching Placebo (n=2) x 1 day

    Drug: LB-102

  • Active comparator
    Part A Cohort 2

    LB-102 15 mg (n=6) or Matching Placebo (n=2) x 1 day

    Drug: LB-102

  • Active comparator
    Part A Cohort 3

    LB-102 100 mg (n=6) or Matching Placebo (n=2) x 1 day

    Drug: LB-102

  • Active comparator
    Part A Cohort 4

    LB-102 200 mg (n=6) or Matching Placebo (n=2) x 1 day

    Drug: LB-102

  • Active comparator
    Part A Cohort 5

    LB-102 150 mg (n=6) or Matching Placebo (n-2) x 1 day

    Drug: LB-102

  • Active comparator
    Part B Cohort 6

    LB-102 50 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)

    Drug: LB-102

  • Active comparator
    Part B Cohort 7

    LB-102 100 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)

    Drug: LB-102

  • Active comparator
    Part B Cohort 8

    LB-102 75 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)

    Drug: LB-102

Interventions

  • DrugLB-102

    (N-Methyl amisulpride)

    Also known as: Active Drug

06

What researchers measure

Primary outcomes

  1. Percentage of participants who experience at least one treatment-emergent adverse event (TEAE)

    A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing.

    Time frame: Day 8 (Part A) or Day 15 (Part B)

Secondary outcomes

  1. Tmax: Time to Reach the Maximum Plasma Concentration

    Time to reach the maximum observed plasma concentration for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7).

    Time frame: Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)

  2. Cmax: Maximum Observed Plasma Concentration

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Cmax will be measured for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7).

    Time frame: Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)

  3. AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration

    AUC(0-tlqc) is a measure of total plasma exposure to a drug from time 0 to time of the Last Quantifiable Concentration and will be measured for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7)

    Time frame: Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)

  4. AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose

    AUC(0-24) is a measure of total plasma exposure to the drug from Time 0 to 24 hours post-dose for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 14).

    Time frame: Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)

07

Study locations

1 site
  • Medpace Clinical Pharmacology LLC
    Cincinnati, Ohio 45227, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jul 2020, 5 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2019
First posted
Dec 5, 2019
StartActual
Jan 22, 2020
Primary completionActual
Jul 1, 2020
CompletionActual
Nov 9, 2020
Last update
Dec 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04187560
Lead sponsor
LB Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Jan 22, 2020
Primary completion
Jul 1, 2020
Completion
Nov 9, 2020
Last update
Dec 10, 2020

Study contacts

Lukasz Biernat, MD
principal investigator · Medpace, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LB-102

Start the discussion